Huntexil® (pridopidine, previously designated ACR16) is a dopaminergic stabiliser which NeuroSearch is evaluating in a clinical Phase III programme in Huntington’s disease with the aim of registering and marketing the product as one of the first specific treatments for patients suffering from this severe disease. Huntington’s disease is a relatively rare hereditary neurodegenerative genetic disorder leading to the degeneration of brain tissue. In several studies Huntexil® has demonstrated highly promising effects on a number of the very disabling symptoms related to the disease.
